[Congressional Record Volume 156, Number 108 (Wednesday, July 21, 2010)]
[Senate]
[Pages S6085-S6086]
From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]

      By Mr. COBURN:
  S. 3627. A bill to ensure that United States global HIV/AIDS 
assistance prioritizes saving lives by focusing on access to treatment; 
to the Committee on Foreign Relations.
  Mr. COBURN. Mr. President, I rise today to discuss the introduction 
of S. 3627, The HIV/AIDS Save Lives First Act of 2010. This important 
piece of legislation will make crucial improvements to our approach to 
bilateral global AIDS efforts. As a practicing physician and former co-
chair of President Bush's Advisory Council on HIV/AIDS, I have 
introduced this bill to ensure that our global AIDS continue to 
prioritize life-saving medical treatment and reduce the transmission of 
the disease from mother to child.
  The President's Emergency Plan for AIDS Relief--known as PEPFAR--has 
been wildly successful and has begun to reverse the course of the AIDS 
epidemic worldwide. Two and half million HIV/AIDS patients from 30 
different countries currently have access to lifesaving treatment 
because of PEPFAR. A 2009 report found that from 2004-2007 as many as 
1.2 million lives had been saved because of the program.
  In 2008, Congress and the President in an overwhelmingly bipartisan 
fashion passed the Tom Lantos and Henry J. Hyde United States Global 
Leadership Against HIV/AIDS, Tuberculosis, and Malaria Reauthorization 
Act of 2008 to continue the important life-saving work of the PEPFAR 
program.
  It is of grave concern, then, that our fight against AIDS is now at 
risk of failure. A recent New York Times article, ``At Front Lines, 
AIDS War Is Falling Apart,'' details how hundreds of thousands of 
patients are being denied promised care in countries such as Uganda--a 
country once held up as PEPFAR's success story. Government officials 
have confirmed the rationing of treatment slots and have advised their 
partners to support ``an equitable system of triage for total ART 
[antiretroviral drug treatment]
slots. . . .''
  Former UNAIDS chief Dr. Piot remarked about past success and doubts 
about the future: ``Then, we were at a tipping point in the right 
direction,'' he explained. ``Now I'm afraid we're at a tipping point in 
the wrong direction.''
  We must not lose sight of the fact that HIV/AIDS is a disease that we 
can diagnose, treat, and prevent. Not only does treatment save lives--
it is the best prevention tool we have. Treatment lowers viral loads, 
which reduces the likelihood of individuals spreading the disease by as 
much as 92 percent. Treatment reduces transmission among partners, 
eliminates baby AIDS, and keeps those with HIV in the medical system 
where they can receive proper counseling and care. And the availability 
of treatment is integral to promoting HIV/AIDS testing and early 
diagnosis.
  With the U.S. spending more than $6.7 billion on global AIDS efforts, 
we are not losing the war on AIDS due to lack of commitment or 
resources. Instead, we are losing because of misplaced priorities.
  We can eliminate the tragedies of baby AIDS and AIDS orphans and 
prevent the spread of HIV by focusing on saving lives by expanding 
access to treatment.
  It costs less than $300 a year to keep someone with HIV healthy and 
alive, about the same price to cover the airfare to send each of the 
25,000 participants to the ongoing AIDS conference in Vienna. If saving 
lives is truly our priority, we must ask every time we spend a dollar 
intended for AIDS relief if that dollar would be better spent paying 
for lifesaving treatment that would keep a mother alive, a family 
together, or a baby born free of the virus.
  If you ask Africans what PEPFAR is, they will tell you it is about 
AIDS treatment. It is the treatment component of PEPFAR that has made 
it the most successful U.S. humanitarian effort in history because it 
has literally saved the lives of millions, preserved families and 
communities, and rescued countless babies from being born with an AIDS 
death sentence.
  The PEPFAR program's long-term success relies on the promise of life-
saving medical treatment to those in need. Unfortunately, according to 
a recent report the recent moratorium on new enrollees in the program 
has already caused an estimated 3,000 deaths.
  The HIV/AIDS Save Lives First Act strengthens the current policy that 
requires a majority of all funding under PEPFAR be spent on life-saving 
HIV/AIDS treatment. Specifically, this legislation would increase the 
treatment allocation to 75 percent of all PEPFAR funding. It also sets 
the modest goal that by 2013 we treat 5 million people with HIV/AIDS.
  Many claim that we cannot treat our way out of this epidemic, but 
they ignore the simple truth that treatment is prevention. Analysts 
from the World Health Organization published research arguing we can 
drastically reduce the transmission of AIDS and virtually halt the 
widening epidemic in Africa within a decade through aggressive routine 
testing and early treatment.
  Other prevention efforts remain an important component of the 
program. Without the reliable promise of access to treatment, however, 
the PEPFAR program will not enjoy long-term success. This legislation 
ensures that the PEPFAR program fulfills its promises, saves the most 
lives possible, and reduces transmission of the disease.
  The HIV/AIDS Save Lives First Act also allocates a small percentage 
of funding for the critical diagnostic screening that must be ramped up 
dramatically if we are to locate and treat every infected person in the 
countries where PEPFAR operates. Finally, the bill acknowledges that 
every baby infected with HIV by her mother during birth or 
breastfeeding is a largely preventable tragedy. The bill would target 
baby AIDS for complete elimination with 100 percent coverage with the 
medical protocols that prevent almost all instances of mother-to-child 
HIV transmission.
  The Save Lives First Act requires recipients of funding to spend no 
more than $500 in annual PEPFAR funding per patient they treat. As 
recently as 2008, documents provided by the administration show that 
the PEPFAR program spent $1,100 in annual treatment costs per patient. 
This is unacceptable--inefficiencies come at the cost of human lives by 
limiting the number of patients PEPFAR can treat.
  The most commonly prescribed drug regimen costs just $64 per year and 
many organizations are providing care to patients for no more than $250 
per year. For example, Doctors Without Borders has had remarkable 
success in achieving treatment efficiencies and now reports that its 
per-patient treatment costs in Malawi were only $237 per year.
  While costs may vary from country to country--and patient to 
patient--it is both reasonable and important that every funding 
recipient under PEPFAR limit their aggregate per patient expenditures 
to $500 per patient. The costs of drug regimens continue to fall 
dramatically, and PEPFAR must take advantage by providing treatment to 
more individuals.
  The HIV/AIDS Save Lives First Act would require that any funding 
recipient under PEPFAR be limited to a treatment allocation of $500 per 
patient treated. This act would also set the modest goal that PEPFAR 
would treat 5 million patients by 2013. If the program's per patient 
expenditures were down to $500 per patient, the program should actually 
treat 6 million patients by 2013, and if everyone were as cost-
effective as Doctors Without Borders, we could be treating 10 million 
patients.
  In the rare instance of a country in which per patient expenditures 
remain above $500 per patient, it is more than reasonable to assume 
that these more developed countries have the resources--along with 
other global partners--to ensure that the per patient treatment 
expenditures ensure access to the highest-quality treatment for each 
patient.
  Everyone can agree that dollars provided to HIV/AIDS treatment should 
go directly to patient care--not bloated administrative budgets. A 
common way of protecting this important principle is to limit the 
administrative budget for PEPFAR funding recipients.
  The HIV/AIDS Save Lives First Act limits administrative overhead to 
10 percent of total expenditures for every

[[Page S6086]]

funding recipient under the program. The bill also limits the State 
Department's administrative budget for PEPFAR to 10 percent of total 
funding.
  Again, treatment is prevention. But this strategy relies on 
identifying HIV positive individuals who are unaware of their status 
and linking them to treatment and counseling. The first step to any 
prevention strategy is an aggressive testing strategy. Unfortunately, 
only about 40 percent of people with HIV in developing countries are 
aware of their status.
  The HIV/AIDS Save Lives First Act sets aside 5 percent of PEPFAR 
funding to dramatically ramp up rapid HIV diagnosis to identify people 
who do not yet know their HIV status in order to get people into 
treatment and early reduce their transmission rates through treatment 
and education.
  This bill also sets a target of conducting 1 billion rapid tests by 
2013 and sets aside 25 percent of testing money to help countries 
implement a policy of universal, opt-out rapid HIV testing.
  Rapid testing and access to treatment are particularly important to 
end baby AIDS, babies being born infected with HIV or becoming infected 
during their first year through breastfeeding, once and for all.
  An estimated 430,000 children were born in 2008 newly infected with 
HIV, mainly through mother to child transmission. About 90 percent of 
these infections occurred in Africa. Only 28 percent of pregnant women 
in Sub-Saharan Africa received an HIV test in 2008. Moreover, the World 
Health Organization reports that access to AIDS drugs is severely 
limited in developing countries, with fewer than 10 percent of pregnant 
women with HIV in those countries having access to medication for their 
own health.
  Of course, dramatic gains are seen when universal testing of pregnant 
women and newborns is provided along with appropriate prophylaxis of 
infections that are that are identified through testing. In the United 
States, new cases of baby AIDS have been virtually eliminated. Studies 
have found that 99 percent of babies were born uninfected if an 
infected mother was diagnosed and proper treatment was administered.
  Botswana, a country that used to have HIV infection rates as high as 
50 percent of child-bearing-aged women, instituted these interventions. 
Ninety-two percent of pregnant women in the country are now being 
tested and the drop in HIV-positive mothers delivering infected babies 
dropped from 35 percent to 4 percent from 2004-2007, with 13,000 HIV-
infected moms being identified annually.
  Prevention of mother-to-child-transmission, PMTCT, is cheap per life 
saved: as of 2008, estimated costs of PMTCT drugs to prevent the spread 
of HIV for (1) mother/child pair was US$167--generics--and US$318--
branded--and the price of drugs and treatment have only declined since.
  The HIV/AIDS Save Lives First Act sets a target of eliminating baby 
AIDS in all PEPFAR countries by 2013, and sets out expectations for how 
to work towards that target by screening 100 percent of pregnant women 
and newborns in PEPFAR countries and providing prophylactic or ARV 
treatment for all HIV-positive moms or babies.
  By emphasizing providing lifesaving treatment under the PEPFAR 
program, we can continue the enormous success we have had in saving 
lives and preventing the spread of this terrible disease. It is my 
sincere hope that my colleagues adopt these common sense policy changes 
that will significantly reduce human suffering, keep families together, 
and save millions of lives.
                                 ______